Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 12,192 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 12,192 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total value of $46,085.76. Following the transaction, the chief executive officer directly owned 509,989 shares in the company, valued at $1,927,758.42. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Voyager Therapeutics Stock Down 1.4%

Shares of NASDAQ:VYGR opened at $3.65 on Thursday. The company has a market capitalization of $202.94 million, a price-to-earnings ratio of -1.69 and a beta of 1.30. The company has a 50 day moving average of $4.02 and a two-hundred day moving average of $4.09. Voyager Therapeutics, Inc. has a 52-week low of $2.64 and a 52-week high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. The business had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. On average, equities analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Wexford Capital LP bought a new position in Voyager Therapeutics during the third quarter worth $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the 4th quarter worth about $44,000. CIBC Asset Management Inc acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $45,000. Bank of Montreal Can bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at about $36,000. Finally, Coldstream Capital Management Inc. acquired a new stake in Voyager Therapeutics during the third quarter worth about $55,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VYGR. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright decreased their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $13.75.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.